Navitoclax (ABT-263)

Name: Navitoclax (ABT-263)
Brand: Selleck Chemicals
SKU: S1001
Rating: 5 (201 reviews)

For research use only.

Catalog No.S1001

201 publications

CAS No. 923564-51-6

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Selleck's Navitoclax (ABT-263) has been cited by 201 publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )
Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )
Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )
Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )
Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )
Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )
Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M3HRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4flOGlEPTB;MD6wNFY3QSEQvF2=	MmWzV2FPT0WU
MV-4-11	NX;rOI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFztfVJKSzVyPUCuNFE2QDZizszN	MmjIV2FPT0WU
NKM-1	NHn1ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrk[2c4UUN3ME2wMlAyPjl7IN88US=>	NFrjPYlUSU6JRWK=
ML-2	M3\iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X2emlEPTB;MD6wNVk5OyEQvF2=	NU\WdFJ[W0GQR1XS
BV-173	NELiTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7rTWM2OD1yLkCyN\|E1KM7:TR?=	NVfFTFEyW0GQR1XS
RS4-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEK1PFch\|ryP	M3nFWHNCVkeHUh?=
HL-60	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnmTWM2OD1yLkCyPVA5KM7:TR?=	NYexXGdHW0GQR1XS
KY821	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2raUmlEPTB;MD6wNlk4PSEQvF2=	NV\hZo1NW0GQR1XS
ECC10	M1\5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVL0[3dRUUN3ME2wMlA{Pzl{IN88US=>	MlXpV2FPT0WU
NCI-H720	NGCwNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPmTWM2OD1yLkC0NFEyKM7:TR?=	NEnWO2JUSU6JRWK=
QIMR-WIL	M{O5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Th[mlEPTB;MD6wOFI5PyEQvF2=	MUnTRW5ITVJ?
KG-1	M3XGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Hqb2lEPTB;MD6wOFQ5PiEQvF2=	NF\XTmpUSU6JRWK=
TGW	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1P1eGlEPTB;MD6wOFY{OyEQvF2=	M4TsSnNCVkeHUh?=
ATN-1	NVv0TFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPRbJZKSzVyPUCuNFQ4OzNizszN	NGHZco1USU6JRWK=
RH-18	M4XJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH6zW4dKSzVyPUCuNFYxPDhizszN	NGWyeoVUSU6JRWK=
EW-18	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLaTWM2OD1yLkC2PFQyKM7:TR?=	M3zBTnNCVkeHUh?=
NB17	NUHjXlJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEexNlQh\|ryP	NV7ZZ3BCW0GQR1XS
SK-NEP-1	NXnwW4lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3tVWlKSzVyPUCuNFczOTNizszN	NHrHTIRUSU6JRWK=
P12-ICHIKAWA	NWLqTo97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPQOpJKSzVyPUCuNFc4PzhizszN	NHXRUXhUSU6JRWK=
KARPAS-45	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorFTWM2OD1yLkC3PFE2KM7:TR?=	NFz2UoxUSU6JRWK=
EW-3	M3W5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInl[5dKSzVyPUCuNFgxPTNizszN	M4jj[3NCVkeHUh?=
NB13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3GTWM2OD1yLkC4NlA{KM7:TR?=	M3Tu[3NCVkeHUh?=
NCI-H209	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrYTWM2OD1yLkC4O\|A1KM7:TR?=	Ml\CV2FPT0WU
NCI-H1092	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMUCyO\|Uh\|ryP	MVjTRW5ITVJ?
NH-12	NV7sSGh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzocXFKSzVyPUCuNVA4PDRizszN	NFPqdGRUSU6JRWK=
697	M1ztd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13UR2lEPTB;MD6xNFg{QSEQvF2=	MoXIV2FPT0WU
KE-37	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PGb2lEPTB;MD6xNVM4KM7:TR?=	MmfiV2FPT0WU
MOLT-4	NVnKW3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjzZ5Q6UUN3ME2wMlE2OTZ7IN88US=>	MWfTRW5ITVJ?
CHP-134	NIjxXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMU[zNFYh\|ryP	M2LnOXNCVkeHUh?=
D-283MED	M{DiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MomyTWM2OD1yLkG3Olg3KM7:TR?=	MmrOV2FPT0WU
LU-135	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX2TWM2OD1yLkG4OVUzKM7:TR?=	MlzIV2FPT0WU
LU-134-A	NGjpfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX1TWM2OD1yLkG4OlcyKM7:TR?=	NHvRdVFUSU6JRWK=
EM-2	NVzNR\|FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMUm5NVgh\|ryP	M2G2OHNCVkeHUh?=
LU-139	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfUbHBuUUN3ME2wMlIxPDl6IN88US=>	Mo\oV2FPT0WU
ALL-PO	NH7w[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PLNGlEPTB;MD6yNVk5QCEQvF2=	NUHmOXc5W0GQR1XS
NB12	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\HeGlEPTB;MD6yN\|EyPSEQvF2=	NVnXfXlHW0GQR1XS
KP-N-YN	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{j5UWlEPTB;MD6yN\|U4OyEQvF2=	NHXoZ45USU6JRWK=
BEN	NFrvN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nLRWlEPTB;MD6yN\|k3QCEQvF2=	NITjO5dUSU6JRWK=
HCC1569	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLvdYM{UUN3ME2wMlI2OTB4IN88US=>	NWC1WYV1W0GQR1XS
HuO9	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMk[3NVUh\|ryP	M{P0TXNCVkeHUh?=
WM-115	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmm5TWM2OD1yLkK3O\|M5KM7:TR?=	NGHxT2hUSU6JRWK=
CCRF-CEM	NUi5cpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwM{O1Nlkh\|ryP	MlLKV2FPT0WU
IST-SL1	NVLvTnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwM{WzOFMh\|ryP	M1rBbHNCVkeHUh?=
BE-13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjLPGJKSzVyPUCuN\|Y1PTlizszN	MonxV2FPT0WU
COR-L88	NH\MZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTSZlhPUUN3ME2wMlM3PTRizszN	NFz5UIZUSU6JRWK=
DOHH-2	NVzhSlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[5XWlEPTB;MD60NVAzOyEQvF2=	MXrTRW5ITVJ?
A704	MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLUTWM2OD1yLkSyOlch\|ryP	MlHsV2FPT0WU
KNS-81-FD	MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL0TWM2OD1yLkS0NFE4KM7:TR?=	NVjhXVZtW0GQR1XS
RPMI-8226	M1zad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTZbmNyUUN3ME2wMlQ2PjV{IN88US=>	M2\Sd3NCVkeHUh?=
TGBC24TKB	NIn2WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoD2TWM2OD1yLkS1O\|c5KM7:TR?=	M1jpSXNCVkeHUh?=
NCI-H1304	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIf3NJdKSzVyPUCuOFYyPTdizszN	NYD0VXY6W0GQR1XS
MOLT-13	M1PsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XBTGlEPTB;MD60OlYyOyEQvF2=	MkXnV2FPT0WU
EW-22	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzwXFZyUUN3ME2wMlQ3PjdzIN88US=>	NGPrd\|RUSU6JRWK=
MS-1	M3T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XhcWlEPTB;MD60Olk{OyEQvF2=	MXLTRW5ITVJ?
RMG-I	M3;ncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\3cmlEPTB;MD60PVQ3PCEQvF2=	MYDTRW5ITVJ?
NTERA-S-cl-D1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUmweFM2UUN3ME2wMlUxODF7IN88US=>	NUDmelR4W0GQR1XS
NCI-H1048	NGryfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwNUC5OVMh\|ryP	NUH1S4R2W0GQR1XS
SW1417	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HpcmlEPTB;MD61OVQ{QCEQvF2=	MXjTRW5ITVJ?
DB	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwNUewPEDPxE1?	NV\0[5Z2W0GQR1XS
MEG-01	NYmyU\|FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETId2pKSzVyPUCuOVg{OiEQvF2=	NGHL[m5USU6JRWK=
EW-13	NFjmd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDoNlJKSzVyPUCuOVg{PDFizszN	MkCyV2FPT0WU
LAMA-84	NXT4[WxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXOy[Id[UUN3ME2wMlU6OjB5IN88US=>	MnfLV2FPT0WU
J-RT3-T3-5	NYXaO2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfJeo9KSzVyPUCuOlA5ODhizszN	M2PxWXNCVkeHUh?=
MOLT-16	NV24eVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf1PI5MUUN3ME2wMlY2OjZ2IN88US=>	MUnTRW5ITVJ?
DU-4475	M4fDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljQTWM2OD1yLk[1OFI4KM7:TR?=	MW\TRW5ITVJ?
HAL-01	NWPTWmdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL6ToE6UUN3ME2wMlczPTR7IN88US=>	M334SHNCVkeHUh?=
RD	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml62TWM2OD1yLke1PFk6KM7:TR?=	NIfIe2ZUSU6JRWK=
OAW-28	NXXNSZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;zZmlEPTB;MD63PFM4KM7:TR?=	NELQZnlUSU6JRWK=
HCC38	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXSS\|ZKSzVyPUCuPFAyQSEQvF2=	MmnyV2FPT0WU
NMC-G1	NIO0VGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwOEGxNlEh\|ryP	NE\BOVFUSU6JRWK=
EW-16	NH6zUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDYTWM2OD1yLkixN\|I5KM7:TR?=	NI\PeHRUSU6JRWK=
DU-145	NFn1To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\nTGlEPTB;MD64PVkzOyEQvF2=	NUCwdJl4W0GQR1XS
HPAF-II	NHvNPWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor0TWM2OD1yLkmyOlI5KM7:TR?=	NHLDelFUSU6JRWK=
A427	M4roZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnseWFKSzVyPUCuPVMxOjJizszN	NYXhPVZDW0GQR1XS
PA-1	NXjJRW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwOUW2OFIh\|ryP	NIG5c2lUSU6JRWK=
OAW-42	NHy5bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3ETWM2OD1yLkm2NVQ3KM7:TR?=	NUmxb5UzW0GQR1XS
L-428	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fVVGlEPTB;MT6wNVI2KM7:TR?=	NFHoSZJUSU6JRWK=
COLO-824	M1mxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v4VWlEPTB;MT6wNVcxQCEQvF2=	NF7pTVZUSU6JRWK=
P30-OHK	NFPVUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHvOFZKSzVyPUGuNFQ3QDhizszN	MWjTRW5ITVJ?
NCI-H2170	NF3mV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTOcHh6UUN3ME2xMlA3OjNizszN	M123U3NCVkeHUh?=
HCC2998	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;xWpdsUUN3ME2xMlA4OTN3IN88US=>	M{DsOHNCVkeHUh?=
NB14	NGHNOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PLdWlEPTB;MT6xN\|c1QCEQvF2=	MkC0V2FPT0WU
TGBC1TKB	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{[5WGlEPTB;MT6xOFE2OiEQvF2=	NGnRTXBUSU6JRWK=
KP-N-YS	M2i0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DaO2lEPTB;MT6xOlI{PiEQvF2=	MVfTRW5ITVJ?
CAL-120	Mm\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rCZmlEPTB;MT6xOlQzQSEQvF2=	MmP6V2FPT0WU
SBC-1	MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDvTWM2OD1zLkG5NFU{KM7:TR?=	M3u4NXNCVkeHUh?=
C32	NXzCb\|RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWWzSpNJUUN3ME2xMlE6ODh6IN88US=>	NU[zTWNQW0GQR1XS
HCC2157	M3e0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLzTHhKSzVyPUGuNVk1QTRizszN	M4\nO3NCVkeHUh?=
COLO-792	M{X0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{O0XmlEPTB;MT6yNFA4OSEQvF2=	NX76S5pYW0GQR1XS
ES7	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrXU4RKSzVyPUGuNlc6PTFizszN	NV\YW4hSW0GQR1XS
HEL	NFfkV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPkUWNKSzVyPUGuN\|ExOjlizszN	NFGyWnhUSU6JRWK=
ES4	NUTEfG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwM{S5PVgh\|ryP	M1O5PXNCVkeHUh?=
NCI-SNU-1	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;3XnpsUUN3ME2xMlM3PTV3IN88US=>	MoLOV2FPT0WU
MDA-MB-415	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rsVWlEPTB;MT6zPFg2KM7:TR?=	MknSV2FPT0WU
NCI-H2342	NFfwd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnZe2hVUUN3ME2xMlQxOjZ7IN88US=>	NWWxcFZ[W0GQR1XS
NB69	NH3WUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwNE[yO\|Eh\|ryP	MULTRW5ITVJ?
D-247MG	NXLJNFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\Me4lKSzVyPUGuOVEyOjJizszN	NXPnToZlW0GQR1XS
SCC-4	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvFdWRxUUN3ME2xMlU6QDh5IN88US=>	MVPTRW5ITVJ?
HuH-7	NWXRNW93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFwNkeyPVMh\|ryP	NEK1cZFUSU6JRWK=
A388	M4ftfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XuT2lEPTB;MT62PFczPCEQvF2=	NITIWXhUSU6JRWK=
Calu-3	MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFwN{C2PVch\|ryP	NGK4OYlUSU6JRWK=
NCI-H1648	NGO2cmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fPcGlEPTB;MT63NVQyQCEQvF2=	MoH2V2FPT0WU
NCI-H2052	M{\OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlWxTWM2OD1zLkeyNlAyKM7:TR?=	NHOyT4ZUSU6JRWK=
Ramos-2G6-4C10	NF7NfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTFwN{O2OVYh\|ryP	NXzWWoVzW0GQR1XS
DEL	M{Lubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4j1XmlEPTB;MT63OFY6OiEQvF2=	M3:3SXNCVkeHUh?=
SNU-423	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETCS3VKSzVyPUGuO\|gyPTdizszN	NWC3R\|hnW0GQR1XS
COR-L23	NGfMeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTFwN{m4O\|Qh\|ryP	NXjDU3BXW0GQR1XS
OMC-1	M1G4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHqZmhKSzVyPUGuPFYxOTZizszN	NG\mZZBUSU6JRWK=
EW-11	NWn1V4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITVU3BKSzVyPUGuPVU3PTdizszN	MX7TRW5ITVJ?
HSC-3	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2CyRWlEPTB;MT65OlM3PSEQvF2=	Mo\lV2FPT0WU
MLMA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTjTWM2OD1zLkm2Olc4KM7:TR?=	MYfTRW5ITVJ?
RCM-1	M33JcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jPbWlEPTB;Mj6wNFM6QSEQvF2=	MmL5V2FPT0WU
MFE-280	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS1d4E1UUN3ME2yMlAzQDR6IN88US=>	NHvyVGxUSU6JRWK=
ES8	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2n0eGlEPTB;Mj6yOVQ4OSEQvF2=	NXvleItrW0GQR1XS
TE-11	NVHpXXNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnoTWM2OD1{LkK5OFc{KM7:TR?=	NYTrU2d4W0GQR1XS
HuO-3N1	NFLSc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvZNYNKSzVyPUKuOFg4QCEQvF2=	M3vsPHNCVkeHUh?=
MHH-NB-11	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLtU2JKSzVyPUKuOVEyPThizszN	MXPTRW5ITVJ?
TGBC11TKB	NFe3WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO2S3FKSzVyPUKuOVc3QDFizszN	M2OwbXNCVkeHUh?=
HOP-92	NHL5eHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jQNmlEPTB;Mj61PFc1OyEQvF2=	MUHTRW5ITVJ?
IGR-1	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTJwNkKwN\|Uh\|ryP	MVzTRW5ITVJ?
GOTO	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTJwNkWzO\|ch\|ryP	MojpV2FPT0WU
NCI-H1650	NWX2eXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\xe2dKSzVyPUKuO\|IzOTVizszN	MlmxV2FPT0WU
NCI-H1581	M{P1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jXN2lEPTB;Mj63PVY5OSEQvF2=	NUDDTld4W0GQR1XS
NCI-H2405	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHSRVZPUUN3ME2yMlgzPzh{IN88US=>	NHvwWWlUSU6JRWK=
U-118-MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vSNWlEPTB;Mj65OlQ6OSEQvF2=	MXLTRW5ITVJ?
DoTc2-4510	NVjqT5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjSTWM2OD1\|LkCxOFE4KM7:TR?=	M2PIWnNCVkeHUh?=
NCI-H596	NH7pZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrmSnlYUUN3ME2zMlA1QTl5IN88US=>	M3nNV3NCVkeHUh?=
MPP-89	NXXpUJprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTNwMEW2OlYh\|ryP	NUS1cWtyW0GQR1XS
GCIY	NGDFTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTNwMkC0PVEh\|ryP	M2fiOXNCVkeHUh?=
SW626	NGjZZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTNwMkS1OFMh\|ryP	MlzWV2FPT0WU
OCI-AML2	NES4UXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnITWM2OD1\|LkOxNlczKM7:TR?=	NF;ZTGtUSU6JRWK=
NBsusSR	NYfqfplOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qxS2lEPTB;Mz6zOFk{QCEQvF2=	NIrlR4dUSU6JRWK=
AN3-CA	M1rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXmdW13UUN3ME2zMlQ1OjN6IN88US=>	MlTJV2FPT0WU
EFM-19	NVfneFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2KzSGlEPTB;Mz60PFM{QSEQvF2=	NEC3OYlUSU6JRWK=
RVH-421	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXQbmxlUUN3ME2zMlU3QDd5IN88US=>	MVzTRW5ITVJ?
5637	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{j5cWlEPTB;Mz62NVExOyEQvF2=	NH3le4RUSU6JRWK=
PANC-08-13	M1LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTNwNkO0O\|Ih\|ryP	NUDQbJYyW0GQR1XS
H9	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTNwNkexOFQh\|ryP	MUHTRW5ITVJ?
KARPAS-299	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjQPXdKSzVyPUOuOlc{PjFizszN	MW\TRW5ITVJ?
TE-5	NH[2[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fIZmlEPTB;Mz63NFcxQSEQvF2=	MXTTRW5ITVJ?
NOS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPYW\|VKSzVyPUOuO\|k5OzRizszN	MYLTRW5ITVJ?
HH	M{jERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLINVNKSzVyPUOuPFM5PjhizszN	NI\jN5dUSU6JRWK=
769-P	NWTCcYFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTNwOEm1NUDPxE1?	Mn3xV2FPT0WU
CHP-212	NIX2UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf0TWM2OD1\|LkmyOVQ6KM7:TR?=	NYjROZFNW0GQR1XS
NCI-H82	M{Xmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTNwOUW5N\|Yh\|ryP	NUjYeGFNW0GQR1XS
Mo-T	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYD4PIxOUUN3ME20MlA1OzF{IN88US=>	NGCzc3NUSU6JRWK=
BB65-RCC	NIe1fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTRwMESzPVkh\|ryP	M4jyOnNCVkeHUh?=
SW1990	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPBNHRkUUN3ME20MlA2QTB6IN88US=>	MkDsV2FPT0WU
LK-2	NEXadG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTRwMUGyPVMh\|ryP	MUnTRW5ITVJ?
ES5	MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIL6UXFKSzVyPUSuNVM6QDVizszN	MVHTRW5ITVJ?
JVM-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfOT21NUUN3ME20MlE5OjJ{IN88US=>	MXPTRW5ITVJ?
RPMI-7951	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PFbGlEPTB;ND6yNlQyOyEQvF2=	NHXZVlNUSU6JRWK=
Calu-6	M3nicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfBcYFKSzVyPUSuNlc5QDFizszN	MYPTRW5ITVJ?
LC-2-ad	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv0TWM2OD12LkK5OVY5KM7:TR?=	Mo[xV2FPT0WU
SW954	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILmVWhKSzVyPUSuNlk3PiEQvF2=	NUW0VIpXW0GQR1XS
H-EMC-SS	NXft[oNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH30NZVKSzVyPUSuN\|E5OzFizszN	MnjGV2FPT0WU
ES3	M3\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTRwM{W0OFEh\|ryP	Ml72V2FPT0WU
no-11	M4KwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXThdo9PUUN3ME20MlM2PTV2IN88US=>	NIOxb3NUSU6JRWK=
LAN-6	M2fscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2i5OGlEPTB;ND60OVE5QSEQvF2=	Mm\mV2FPT0WU
FTC-133	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTRwNUO5OUDPxE1?	M336SnNCVkeHUh?=
8505C	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTRwNUSyN{DPxE1?	NYXzXGJGW0GQR1XS
SW620	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ITWM2OD12LkW3NFU4KM7:TR?=	NIHXSWpUSU6JRWK=
BCPAP	NF\SeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq5dY5nUUN3ME20MlY{PDhzIN88US=>	NEKw[4tUSU6JRWK=
SK-LU-1	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjkTWM2OD12Lk[2NFg6KM7:TR?=	NF\BUZhUSU6JRWK=
NCI-H1623	NXzaZWtiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIe0fYVKSzVyPUSuO\|AzOjhizszN	MXTTRW5ITVJ?
C2BBe1	NFHMXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fWdGlEPTB;ND63OFAxQCEQvF2=	NE\Yc\|BUSU6JRWK=
GP5d	NG\pWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXie\|dKSzVyPUSuO\|g{QDhizszN	NUfhXHhGW0GQR1XS
NB6	NUGzWZNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP2TWM2OD12Lki2NlA1KM7:TR?=	MnHsV2FPT0WU
MDA-MB-157	M1HCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjKbY5UUUN3ME20Mlg5PzZizszN	MYjTRW5ITVJ?
UMC-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3RTWM2OD12Lki4PVY1KM7:TR?=	M3HVbXNCVkeHUh?=
HCC1419	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{juR2lEPTB;ND65NFA3OyEQvF2=	M2f0VnNCVkeHUh?=
NCI-H2029	M4nQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTRwOUSxPFUh\|ryP	MWXTRW5ITVJ?
LXF-289	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnVdmZkUUN3ME21MlA{PzF7IN88US=>	NXTSe29lW0GQR1XS
KINGS-1	NXHDbYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{X2NmlEPTB;NT6wO\|c1PCEQvF2=	MUPTRW5ITVJ?
HD-MY-Z	NH3xTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{W0V2lEPTB;NT6yN\|k3QSEQvF2=	MkX1V2FPT0WU
ESS-1	NVvBb3JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnuXldvUUN3ME21MlI2PTl5IN88US=>	MonlV2FPT0WU
GI-1	NF7ZeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTVwMke5NlYh\|ryP	MkSzV2FPT0WU
RPMI-2650	M2XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlexTWM2OD13LkO2NVYh\|ryP	NGOwepdUSU6JRWK=
IA-LM	M1:1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPFNohJUUN3ME21MlM6QDdzIN88US=>	NHPiOHVUSU6JRWK=
KP-4	NWnmeXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TiU2lEPTB;NT60OlM{PCEQvF2=	NHnsWlJUSU6JRWK=
G-402	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\6NWdIUUN3ME21MlUyQDZ3IN88US=>	MmD0V2FPT0WU
OS-RC-2	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi4WldNUUN3ME21MlUzPjB2IN88US=>	NUniN2syW0GQR1XS
NCI-H1155	M2rkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTVwNUS5OVUh\|ryP	MX\TRW5ITVJ?
OE19	NHzSdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Lt[WlEPTB;NT62PFYzPCEQvF2=	NHz1d3dUSU6JRWK=
U-2-OS	NUWwWGtQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HTfGlEPTB;NT64PVAyOyEQvF2=	NETteoxUSU6JRWK=
SCC-15	NFXzdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTVwOUO2OlIh\|ryP	NUX5Z5k1W0GQR1XS
NCI-H630	MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTp[VFKSzVyPUWuPVk1ODRizszN	MmKzV2FPT0WU
PFSK-1	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLhTWM2OD14LkC1NlU6KM7:TR?=	M2XvcnNCVkeHUh?=
NCI-H1770	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ziZmlEPTB;Nj6yNFg4PCEQvF2=	M2LqeHNCVkeHUh?=
SK-MEL-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoD5TWM2OD14LkSyPVE2KM7:TR?=	M3qyN3NCVkeHUh?=
LB1047-RCC	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnEbGY2UUN3ME22MlQ4PjJ3IN88US=>	M4TsfHNCVkeHUh?=
NCI-H446	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37iTWlEPTB;Nj62NlkzPSEQvF2=	MX;TRW5ITVJ?
SW780	M3nBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTLTWM2OD14LkewNVg2KM7:TR?=	NWLrT4dbW0GQR1XS
NEC8	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrY[JpoUUN3ME22Mlc3PjNizszN	MWjTRW5ITVJ?
NOMO-1	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTZwN{ixNVEh\|ryP	M4X6VHNCVkeHUh?=
COLO-668	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXhSYlEUUN3ME22Mlg1Ozh5IN88US=>	NHfpcHFUSU6JRWK=
MC116	M{PsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTZwOUO4PVch\|ryP	NIjUcI5USU6JRWK=
HCC1937	MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XhZ2lEPTB;Nj65PVI2OSEQvF2=	NYf3bIEzW0GQR1XS
NCI-N87	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LwVGlEPTB;Nz6xPVI6OyEQvF2=	M3njVXNCVkeHUh?=
COLO-320-HSR	NETZ[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn1TWM2OD15LkKyO\|M5KM7:TR?=	MV\TRW5ITVJ?
HCC1806	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzkfldKSzVyPUeuNlYxPDRizszN	MXvTRW5ITVJ?
OVCAR-3	NFnN[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnrTWM2OD15LkOzNFM5KM7:TR?=	NFPVcnVUSU6JRWK=
NUGC-3	NVfsZ5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTdwM{m2PVQh\|ryP	MmfaV2FPT0WU
SW1783	NG\IeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPCdVNKSzVyPUeuOFMyPzVizszN	MVLTRW5ITVJ?
GCT	NELKSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTdwNU[5NFYh\|ryP	MXnTRW5ITVJ?
NCI-H2126	NXv3ZYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjDTWM2OD15LkezOlI2KM7:TR?=	NF\tXnhUSU6JRWK=
MEL-HO	M{\VUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjwTWM2OD15Lke3NFU1KM7:TR?=	NV;TSnlSW0GQR1XS
CAPAN-1	MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rxTGlEPTB;Nz63O\|M2PyEQvF2=	MlzpV2FPT0WU
SW756	NWDaPXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\KeGlEPTB;Nz63PFM{OyEQvF2=	MV;TRW5ITVJ?
SKG-IIIa	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDJXpRKSzVyPUeuPFE5QTJizszN	NUXVRWJPW0GQR1XS
HCE-T	NGK3[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX0doVKSzVyPUeuPFc4QDNizszN	NGKxTFBUSU6JRWK=
Ca-Ski	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjzSodKSzVyPUeuPVk{QDNizszN	Mm\1V2FPT0WU
COLO-684	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRThwMEG4NVgh\|ryP	MX7TRW5ITVJ?
KYSE-70	NFnXTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvSTWM2OD16LkC3O\|I6KM7:TR?=	Mn2zV2FPT0WU
TI-73	MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfJU4oxUUN3ME24MlI2QDVzIN88US=>	M1fRUnNCVkeHUh?=
BT-20	M2XKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvVco5kUUN3ME24MlI3ODV{IN88US=>	MX;TRW5ITVJ?
MHH-ES-1	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRThwNUG4N\|Qh\|ryP	M2XCeHNCVkeHUh?=
TE-12	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPhTWM2OD16LkW5PVMyKM7:TR?=	MnHNV2FPT0WU
YH-13	NFfqZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\STWM2OD16Lk[xNFA5KM7:TR?=	MnrXV2FPT0WU
SF126	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrKTWM2OD16LkizPFY2KM7:TR?=	NXfyOXc2W0GQR1XS
J82	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnzUnRKSzVyPUiuPVAxOzhizszN	NW[0TI95W0GQR1XS
RCC10RGB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X1UWlEPTB;OD65PVU3OSEQvF2=	MUTTRW5ITVJ?
SK-UT-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDITWM2OD17LkC0PVQ2KM7:TR?=	Moj0V2FPT0WU
LB2241-RCC	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTlwMUmxN\|ch\|ryP	NWnzN\|Z4W0GQR1XS
LB996-RCC	NV;sWYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2P1XGlEPTB;OT6xPVg6KM7:TR?=	Mn7BV2FPT0WU
EPLC-272H	M1XBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4L6V2lEPTB;OT6zO\|Y2PyEQvF2=	MXrTRW5ITVJ?
CTV-1	NFvOSlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PqWGlEPTB;OT61OlU{OiEQvF2=	M1G3VnNCVkeHUh?=
HSC-2	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTlwNUe1OUDPxE1?	NW\H[plNW0GQR1XS
SK-MEL-28	M130XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LBZ2lEPTB;OT62NVg6OyEQvF2=	M{PPPHNCVkeHUh?=
MMAC-SF	NYPPNGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnhNVZKSzVyPUmuOlg4PSEQvF2=	M1vrdXNCVkeHUh?=
CP50-MEL-B	NXPvbnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C2XGlEPTB;OT63OVc5OiEQvF2=	M3;xN3NCVkeHUh?=
HT-1080	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDWT\|VQUUN3ME25Mlc4PzN7IN88US=>	NHnOXGxUSU6JRWK=
HEC-1	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTFyLkOzOVIh\|ryP	MUfTRW5ITVJ?
AGS	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nUZWlEPTB;MUCuN\|c1KM7:TR?=	MmnqV2FPT0WU
GAMG	NHO4NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\kTWM2OD1zMD61NVYzKM7:TR?=	M1frOXNCVkeHUh?=
SW48	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zDVGlEPTB;MUCuOVE5QSEQvF2=	M{DzdXNCVkeHUh?=
U031	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7XcVNjUUN3ME2xNE42QTB6IN88US=>	M1G2cXNCVkeHUh?=
OVCAR-5	M4\RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTFyLk[0Nlkh\|ryP	MX3TRW5ITVJ?
SF295	NXzFNW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorsTWM2OD1zMD62O\|A1KM7:TR?=	NGPsOndUSU6JRWK=
BHT-101	NIfT[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTFyLkexO\|ch\|ryP	M3\BWHNCVkeHUh?=
VMRC-RCZ	NH;ObZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnrbY5KSzVyPUGxMlMzODFizszN	M1;OUHNCVkeHUh?=
ACHN	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nhTGlEPTB;MUGuOFIyOSEQvF2=	NGLnUWtUSU6JRWK=
NCI-H526	NVLCbJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTFzLkWwOFMh\|ryP	MoHJV2FPT0WU
MN-60	NGHkdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jRdGlEPTB;MUGuOVM6KM7:TR?=	M1LsWHNCVkeHUh?=
NCI-H2291	NF;TWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjpN4xMUUN3ME2xNU42PDZ4IN88US=>	NYjWUW5vW0GQR1XS
SCC-25	M1TBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\xdZg1UUN3ME2xNU44PTV4IN88US=>	NHnufIZUSU6JRWK=
SK-MEL-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\FcGlEPTB;MUGuO\|Y{PyEQvF2=	M1X1eXNCVkeHUh?=
SN12C	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFzLkmzOVUh\|ryP	M2qyTXNCVkeHUh?=
NCI-H69	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3IXYZvUUN3ME2xNk41OjN2IN88US=>	NW\pUVhRW0GQR1XS
ME-180	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTF{LkewOVQh\|ryP	MlLBV2FPT0WU
MC-IXC	NV76T2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTF{Lke1NVgh\|ryP	M{THXXNCVkeHUh?=
NCI-H2347	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7L[\|VMUUN3ME2xNk44PjF2IN88US=>	NUfHPGZNW0GQR1XS
M059J	NU\GNGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4S0W2lEPTB;MUKuO\|czPyEQvF2=	MYXTRW5ITVJ?
A2058	NUDBe\|lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zMWGlEPTB;MUKuPFY5OSEQvF2=	NGjFO\|RUSU6JRWK=
VA-ES-BJ	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTF{Lki3PFUh\|ryP	NEfBd\|dUSU6JRWK=
Ca9-22	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv5Z\|JFUUN3ME2xNk46PDVzIN88US=>	M2TVeHNCVkeHUh?=
KNS-42	NXPESoJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjn[XltUUN3ME2xNk46QTh2IN88US=>	M1fwSXNCVkeHUh?=
LoVo	NHrvdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTF\|LkKzNVMh\|ryP	M1e0bHNCVkeHUh?=
AM-38	MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXITWM2OD1zMz6yOVY3KM7:TR?=	MkTBV2FPT0WU
NB5	NELlUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7MTWM2OD1zMz6zO\|UzKM7:TR?=	MoXWV2FPT0WU
L-363	M1Xhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq2XWg{UUN3ME2xN{41ODN\|IN88US=>	Mlm3V2FPT0WU
SK-MEL-30	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrBdGVmUUN3ME2xOE4xPjR3IN88US=>	MnHOV2FPT0WU
NCI-H1563	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHRTllKSzVyPUG0MlYxOzlizszN	NV3hTFZzW0GQR1XS
NCI-H2228	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTF2Lk[wO\|ch\|ryP	MWHTRW5ITVJ?
MFM-223	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDDTGhKSzVyPUG1MlE5OTNizszN	MljLV2FPT0WU
LB831-BLC	MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLDTWM2OD1zNT6yO\|Y4KM7:TR?=	NXz6eVVSW0GQR1XS
SW872	NUPHW\|FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWOx[Y9iUUN3ME2xOU4{ODh4IN88US=>	MlTaV2FPT0WU
NCI-H522	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj4Nm1KSzVyPUG1MlM{ODZizszN	NVjYXGFtW0GQR1XS
EW-1	NEmybGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HQdWlEPTB;MUWuOVQ3OiEQvF2=	Mo\XV2FPT0WU
HN	NUHHeXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\2TWM2OD1zNT61PVQzKM7:TR?=	NIP0[lRUSU6JRWK=
SW837	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NED3fWZKSzVyPUG1Mlc5PDdizszN	MoHyV2FPT0WU
SCC-9	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH23[I1KSzVyPUG1MlgyOTRizszN	MofRV2FPT0WU
MKN7	NX\nU2VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTiPZJOUUN3ME2xOU46PzN{IN88US=>	NIL3c2FUSU6JRWK=
KYSE-410	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHNVo9KSzVyPUG2MlU6OSEQvF2=	MX\TRW5ITVJ?
SK-N-DZ	M{nMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTF4Lk[xNVYh\|ryP	MmrWV2FPT0WU
COR-L105	NWK3b4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTF4Lk[1Nlgh\|ryP	NInu[INUSU6JRWK=
LB2518-MEL	M4rr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HldGlEPTB;MU[uPFM5QSEQvF2=	NXT1WmhmW0GQR1XS
OVCAR-4	NFPmNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXRTWM2OD1zNj64PFYzKM7:TR?=	NIDqNZFUSU6JRWK=
TK10	M3iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDaTWM2OD1zNj65OFc{KM7:TR?=	NYO0T\|d4W0GQR1XS
KNS-62	Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTFNYdqUUN3ME2xOk46Pzd5IN88US=>	MmPmV2FPT0WU
RPMI-8866	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHniSoZKSzVyPUG3MlE4OzJizszN	MmHWV2FPT0WU
HuP-T4	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEe2e3dKSzVyPUG3MlI1QTVizszN	MmPhV2FPT0WU
CGTH-W-1	M1L6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjrTWM2OD1zNz61NlE6KM7:TR?=	MkDxV2FPT0WU
T-24	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mme5TWM2OD1zNz61N\|Q4KM7:TR?=	MXHTRW5ITVJ?
HT-3	NV3hdXNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{SxOWlEPTB;MUeuOVkyPCEQvF2=	MULTRW5ITVJ?
KS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HINWlEPTB;MUeuOlc{KM7:TR?=	NWL4[m57W0GQR1XS
NCI-H1792	NUHNT2NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzSTWM2OD1zNz63PVgh\|ryP	MkjsV2FPT0WU
ABC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjlZ\|djUUN3ME2xO{45OTRzIN88US=>	MX\TRW5ITVJ?
BPH-1	MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTF6LkG2PFUh\|ryP	MnHzV2FPT0WU
A431	M{XHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIK2SJBKSzVyPUG4MlQyOjdizszN	MXjTRW5ITVJ?
T98G	NUTZO3ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfLTWM2OD1zOD61NVU4KM7:TR?=	MUjTRW5ITVJ?
BHY	NWnJTHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\QTWM2OD1zOD64Olkh\|ryP	MXjTRW5ITVJ?
Capan-2	M4HDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHMTWM2OD1zOD65NFc5KM7:TR?=	NETKSIJUSU6JRWK=
MDA-MB-175-VII	NUXMNZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHpPWNpUUN3ME2xPE46OjB7IN88US=>	Ml;ZV2FPT0WU
CAL-27	M3POSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTF7LkC0PFch\|ryP	NXTpTY9kW0GQR1XS
AsPC-1	NX7UNnNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfUW3pKSzVyPUG5Mlg3PTdizszN	MXHTRW5ITVJ?
KU812	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLaXXJzUUN3ME2xPU46PTd\|IN88US=>	M{nLW3NCVkeHUh?=
NCI-H441	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTJyLkCwNUDPxE1?	NXPl[4hIW0GQR1XS
Mewo	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTJyLkGyPFgh\|ryP	MmnPV2FPT0WU
SK-MEL-24	NFjIcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\pTWM2OD1{MD6xOFc4KM7:TR?=	NG[3PY9USU6JRWK=
NCI-H727	M3[1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHzTWM2OD1{MD6yO\|A1KM7:TR?=	NHjpVpFUSU6JRWK=
EKVX	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJyLk[wOkDPxE1?	NH\rdIhUSU6JRWK=
RT-112	NGXEbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NET0cXZKSzVyPUKwMlYyOjJizszN	Mm\6V2FPT0WU
CAMA-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTJyLkm4NFMh\|ryP	MnXBV2FPT0WU
SW900	NI\LU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfSTWM2OD1{MT6wNVQ6KM7:TR?=	NXztUYFKW0GQR1XS
NCI-H23	NI\lfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDFNmkzUUN3ME2yNU4yOjd5IN88US=>	M2noTnNCVkeHUh?=
SK-PN-DW	NV\IPVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTqfGhKSzVyPUKxMlE3PDlizszN	MmHTV2FPT0WU
BB30-HNC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HoPGlEPTB;MkGuNlc1PSEQvF2=	Ml\YV2FPT0WU
VM-CUB-1	Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnjU\|BwUUN3ME2yNU4{PTN4IN88US=>	NEf5dVJUSU6JRWK=
IST-MEL1	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2T3ZmlEPTB;MkGuN\|Y6OiEQvF2=	M4\peXNCVkeHUh?=
CTB-1	NF\FNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3OTHVKSzVyPUKxMlQ4PTVizszN	MWDTRW5ITVJ?
LCLC-103H	NXu5[XdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTJ{LkG1PFIh\|ryP	M2G5XnNCVkeHUh?=
PANC-03-27	Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXme3NKSzVyPUKyMlUyPjlizszN	M1LBVHNCVkeHUh?=
HTC-C3	NV3RZY52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\OTWM2OD1{Mj61OVU2KM7:TR?=	MYHTRW5ITVJ?
TE-8	NEnGXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHruNZhKSzVyPUKzMlI2PjVizszN	M3nGeHNCVkeHUh?=
NCI-H292	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTJ3LkO1N\|Yh\|ryP	MVHTRW5ITVJ?
COLO-680N	M1\DWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrzdZVNUUN3ME2yOU43OzJ7IN88US=>	NEnKOY9USU6JRWK=
KYSE-520	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJ3Lk[0OEDPxE1?	MmK1V2FPT0WU
NB10	M3znSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTJ4LkOxNVch\|ryP	NI\Wdo9USU6JRWK=
NCI-H661	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHT[4xKSzVyPUK2MlQ4OTNizszN	NUTz[GhMW0GQR1XS
GMS-10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnDcoVYUUN3ME2yOk45PjN6IN88US=>	MU\TRW5ITVJ?
NCI-H2122	NX:2bZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHDVYJKSzVyPUK2Mlk6QThizszN	MluzV2FPT0WU
OVCAR-8	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTJ5LkC2N\|gh\|ryP	MUTTRW5ITVJ?
DJM-1	MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfNWZRKSzVyPUK3MlE1PTRizszN	M2K3RnNCVkeHUh?=
UACC-893	NUjv[5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DaRmlEPTB;MkeuPVg4QCEQvF2=	Mkn0V2FPT0WU
C8166	NYP0XlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVW4OJVGUUN3ME2yPE43QTN6IN88US=>	M1XGUnNCVkeHUh?=
NCI-H1693	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXtcYhKSzVyPUK4MlY6PzVizszN	NIjUcpZUSU6JRWK=
TYK-nu	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXPOFhKSzVyPUOwMlA{PDVizszN	MmfLV2FPT0WU
SW1710	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkj0TWM2OD1\|MD6xNlYh\|ryP	MVTTRW5ITVJ?
A375	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\WdGZJUUN3ME2zNE4{OjR\|IN88US=>	NVvENHlUW0GQR1XS
HMV-II	NUjWZVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TtWmlEPTB;M{GuN\|U6OiEQvF2=	MUTTRW5ITVJ?
NCI-H2087	NET6ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUWzU5JzUUN3ME2zNU43OzV{IN88US=>	NWWxXJFOW0GQR1XS
CAL-54	NUfiXml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfTUZdKSzVyPUOxMlczPDFizszN	MWLTRW5ITVJ?
HCC70	M1nVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF73dlJKSzVyPUOyMlE{QDdizszN	M1GzW3NCVkeHUh?=
ES1	NX7US5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTN{LkOwOlIh\|ryP	NHHXepVUSU6JRWK=
NCI-H1355	NEfFeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTMTWM2OD1\|Mz6yNFQh\|ryP	MX;TRW5ITVJ?
CFPAC-1	NX25OWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PSU2lEPTB;M{OuNlM{OiEQvF2=	MXjTRW5ITVJ?
MKN28	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvnOG5KSzVyPUOzMlM5ODlizszN	M4HJb3NCVkeHUh?=
HDLM-2	NFz6UoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTN\|Lk[5N\|Eh\|ryP	NHzCR\|dUSU6JRWK=
PANC-10-05	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX[wU2J6UUN3ME2zOE4yODF2IN88US=>	Mk\YV2FPT0WU
SAS	NVjM[2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXVUJlCUUN3ME2zOE41PTZ3IN88US=>	NEXXZoVUSU6JRWK=
HCC1395	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTN2LkexPFYh\|ryP	MVXTRW5ITVJ?
8305C	M{HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPKUFdKSzVyPUO1Mlg1OTVizszN	NYPKcVhUW0GQR1XS
KM12	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTN4Lke1OFch\|ryP	NVm1R5plW0GQR1XS
SW1116	Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vwdGlEPTB;M{euOVk6OiEQvF2=	NYnHeYh4W0GQR1XS
SK-MEL-1	NFzFWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkCzTWM2OD1\|OD6zN\|g6KM7:TR?=	NIrTVXhUSU6JRWK=
HCC2218	NHvsSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFz0e3JKSzVyPUO4MlY2OTlizszN	M2f3VHNCVkeHUh?=
T84	NWqzdJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDUTWM2OD1\|OD63OFA6KM7:TR?=	NGX4e\|lUSU6JRWK=
ETK-1	NWTCWmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTN7LkCyNkDPxE1?	MnXmV2FPT0WU
COLO-800	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfQTWM2OD1\|OT6zPFY5KM7:TR?=	NHHtdVdUSU6JRWK=
CAL-12T	M2LNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTuWnBKSzVyPUO5MlUzQDFizszN	M3jmS3NCVkeHUh?=
ACN	NEn4PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTRyLkS5NVEh\|ryP	NE\td3dUSU6JRWK=
SJSA-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTRzLkG1PVYh\|ryP	NGTHPW1USU6JRWK=
PSN1	M3\vdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTRzLkG3OFkh\|ryP	NGi5cXVUSU6JRWK=
D-566MG	M3LS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTRzLkKwPFYh\|ryP	M4q0fXNCVkeHUh?=
EGI-1	NHG3NG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XaVGlEPTB;NEKuOFI5KM7:TR?=	NFn2bXhUSU6JRWK=
A204	NHvUOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmWxTWM2OD12Mj62N\|g5KM7:TR?=	MWfTRW5ITVJ?
Saos-2	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVGyU\|I{UUN3ME20Nk45OzZ7IN88US=>	MWLTRW5ITVJ?
SNU-C2B	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7ab2tKSzVyPUSzMlY5PzhizszN	M3L3XHNCVkeHUh?=
HLE	NVrpUmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:2VGhKSzVyPUS0MlA5PTZizszN	NWD1SZlVW0GQR1XS
SW1463	NWLyeIlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[1TWM2OD12ND65PVcyKM7:TR?=	NFu1PJFUSU6JRWK=
DSH1	NXrNRpVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1O4SGlEPTB;NEWuNFA{OyEQvF2=	NHvPVppUSU6JRWK=
MCF7	NUjVO2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUP4doY6UUN3ME20OU42ODVzIN88US=>	M2fFPHNCVkeHUh?=
K5	M3j3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHieGhKSzVyPUS1Mlk1ODVizszN	MXjTRW5ITVJ?
NCI-H358	NVO1W5FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHPNYdKSzVyPUS3MlIyPSEQvF2=	NEL2[ZZUSU6JRWK=
NCI-H2030	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTR5LkKzO\|Qh\|ryP	M1njdXNCVkeHUh?=
SW948	MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTR5LkS2OEDPxE1?	M1;zdHNCVkeHUh?=
BALL-1	MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXUTWM2OD12Nz62NVY5KM7:TR?=	Mk\JV2FPT0WU
TE-9	NXW3cGdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrVXohKSzVyPUS3Mlk2QDFizszN	MXHTRW5ITVJ?
SK-N-FI	NYDYfWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfVTWM2OD12OD6wN\|U5KM7:TR?=	NVLo[ZQyW0GQR1XS
KALS-1	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlq4TWM2OD12OD6xNlg6KM7:TR?=	NH2zNGpUSU6JRWK=
HO-1-N-1	M2qxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTR6Lke0OFUh\|ryP	Mn;TV2FPT0WU
NCI-H2452	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzUTWNKSzVyPUS5MlEyPTJizszN	NXfmeHVTW0GQR1XS
OC-314	NFnFOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvDTWM2OD12OT62PFM1KM7:TR?=	NFjPNnRUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04480086	Not yet recruiting	Drug: Mivebresib\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	July 31 2020	Phase 1
NCT04454658	Not yet recruiting	Drug: ABBV-744\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	July 14 2020	Phase 1
NCT04041050	Recruiting	Drug: Navitoclax\|Drug: Ruxolitinib	Myeloproliferative Neoplasm	AbbVie	November 8 2019	Phase 1
NCT03181126	Active not recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)